first dose = having drug design/manufacture of large batches squared away
it’ll be a historic moment for the company and the team. We can’t afford any delays given our cash runway, and we can’t have a repeat of the 2 year IND approval delay.
Market is a weighing machine in the long run, hopefully we can start shedding our reputation for untimely delivery and starting achieving a string of value accretive milestones. The BD opportunities will materialize in time as we build the scientific, regulatory and commercial/clinical body of evidence (data and capability).
first dose = having drug design/manufacture of large batches...
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.0¢ |
Change
0.005(2.70%) |
Mkt cap ! $886.5M | |||
| Open | High | Low | Value | Volume |
| 18.5¢ | 19.0¢ | 17.5¢ | $508.8K | 2.763M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 118941 | 18.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.0¢ | 183634 | 2 |
| Last trade - 16.10pm 14/11/2024 (20 minute delay) ? |
| PYC (ASX) Chart |
Day chart unavailable